$SKYH

GESSOW ANDREW J purchased $54K of SKYH

GESSOW ANDREW J purchased 5,000 shares of Sky Harbour Group Corp (SKYH) at $10.85 on 2026-08-14.

Original reporting
SEC EDGAR · GESSOW ANDREW J
Published Aug 18, 2026, 3:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 4:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SKYH
Neutral
low confidence
Mentioned
$SKYH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYHNeutralLow
01

Why it matters

The disclosed event is a director open-market purchase of 5,000 shares at $10.8500, with holdings after the trade of 22,910 shares.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to drive a major fundamental repricing on its own.

03

What to watch

The article does not provide context for the purchase (e.g., compensation, tax planning, or prior trading history), and the absence of a 10b5-1 plan does not guarantee informational advantage.

Relevance 4/10Novelty 3/10Timing: new Form 4 filed 2026-08-18 (after-hours/late session)

Background

The article is a SEC Form 4 insider transaction disclosure for Sky Harbour Group Corp.

Company-level read

Ticker impact

$SKYHNeutralLow confidence
Context

Sky Harbour Group Corp director Andrew J Gessow bought 5,000 shares at $10.8500 on 2026-08-14, totaling $54,250, per Form 4.

Expected impact

Limited near-term impact; any effect is likely small and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is an insider buy without a 10b5-1 plan and with relatively small dollar value; insider transactions often have weak predictive power versus fundamentals.

Market effects

No sector-level implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and may not reflect a change in business outlook.

Key entities

  • Sky Harbour Group Corp

    Subject of the Form 4 insider transaction disclosure.

  • Gessow Andrew J

    Director who purchased 5,000 shares on 2026-08-14.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SKYHMedAI 8/10

Sky Harbour announces $40 million equity financing deal

Sky Harbour Group (SKYH) entered a stock purchase agreement for a registered direct offering of 4,000,000 Class A common shares at $10.00 each, closing Aug. 12, 2026, for $40 million gross proceeds for general corporate purposes. A 90-day lock-up was agreed. Boston Omaha arranged a concurrent secondary sale of 360,000 shares at $10.00, expected to close Aug. 14, 2026.

$SKYHMed

Sky Harbour Group Corp (SKYH): Results of Operations and Financial Condition

Sky Harbour Group Corp (SKYH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sky Harbour Announces Q2 Results and Updates on Leasing, Construction, Funding and Other Activities Reaffirms Guidance for Year End 2026 WEST HARRISON, N.Y.--( BUSINESS WIRE )--Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation

$SKYHMedAI 8/10

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Skyhawk Therapeutics reported 12-month cUHDRS subcomponent results from its Phase 1/2 trial of oral Huntington’s disease candidate SKY-0515. Mean changes vs expected worsening (from Enroll-HD propensity-weighted analyses) were favorable for TFC (+0.07 vs -0.87), TMS (-2.00 vs 2.21), SDMT (-0.19 vs -1.78), and SWRT (+3.44 vs -3.13). CGI/PGI showed no assessed worsening and 65% of participants/50% of clinicians reported improvement; mHTT blood reductions up to 69% and PMS1 mRNA up to 26%.